Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study
J Thorac Dis
.
2012 Dec;4(6):558-61.
doi: 10.3978/j.issn.2072-1439.2012.10.02.
Authors
Millie Das
1
,
Heather Wakelee
Affiliation
1
VA Palo Alto Health Care System, Palo Alto, CA, USA;
PMID:
23205278
PMCID:
PMC3506785
DOI:
10.3978/j.issn.2072-1439.2012.10.02
No abstract available